European Archives - Page 4 of 1374 - European Medical Journal

New Research into Oral Semaglutide and Heart Failure Outcomes

The secondary SOUL trial analysis shows oral semaglutide reduces heart failure events in patients with diabetes and pre-existing heart failure.

PM2.5 Pollution Driven by Residential Wood Burning

Residential wood burning contributes substantially to winter PM2.5 pollution in the USA, linked to thousands of premature deaths.

Menstrual Blood Shows Promise as Alternative Sample for HPV Screening

HPV testing using menstrual blood showed comparable accuracy to clinician-collected samples in detecting high-grade cervical lesions in a large population study.

Factor VIII

EAHAD 2026: Factor VIII Activity Measurement Improves with Calibrators

Presented at EAHAD 2026 and awarded third best poster, this multicentre study demonstrates that product-specific calibration improves the accuracy of factor VIII activity measurement across assay platforms.

Antimicrobial Resistance Threatens Children Across Oceania

Drug-resistant infections such as MRSA are widespread among children in Oceania, with major gaps in access and approved treatments.

Novel Non-Invasive Liver Fibrosis Tests Are Effective Biopsy Alternatives

Novel non-invasive liver disease assessments (NILDAs) are effective liver biopsy alternatives for fibrosis, a 2026 systematic review has found.

MRI Radiomics May Help Stratify Rectal Cancer Risk

MRI-based radiomics models may help predict tumour deposit burden in rectal cancer, with a fusion AI approach outperforming radiologists in preoperative risk assessment.

Acute Pancreatitis Warnings Strengthened on GLP-1RAs

The UK’s MHRA has strengthened warnings of acute pancreatitis on GLP-1RAs, following rare reports of necrotising and fatal pancreatitis.

childhood allergy

Advanced Maternal Age and Childhood Allergy Risk

Children born to older mothers showed lower risks of food allergy, wheezing, and allergen sensitisation in early childhood, suggesting advanced maternal age may have a protective role.

Low Midlife PSA Linked to Reduced 20-Year Prostate Cancer Risk

Low Midlife PSA Linked to Reduced 20-Year Prostate Cancer Risk

A 20-year cohort study shows men with low baseline PSA face minimal prostate cancer risk, supporting personalised screening strategies using PSA and PSA density.